SyntekaBio

SyntekaBio DSCR

The Debt Service Coverage Ratio (DSCR) of SyntekaBio (226330.KQ) as of Nov 20, 2026 is -33.82. In the previous year, Debt Service Coverage Ratio (DSCR) was -0.70 — a change of 4,736.09% (lower).

DSCR

-33.82

YoY

4,736.09%

Last updated:

Debt Service Coverage Ratio (DSCR) of SyntekaBio is 2022 -33.82 . Debt Service Coverage Ratio (DSCR) of SyntekaBio was 2021 -0.70 . It decreases by 4,736.09% lower compared to the previous year.

The SyntekaBio DSCR history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

DSCR
Date
DSCR
Jan 1, 2017
-7.11 KRW
Jan 1, 2019
-21.84 KRW
Jan 1, 2020
-8.45 KRW
Jan 1, 2021
-0.70 KRW
Jan 1, 2022
-33.82 KRW
The SyntekaBio DSCR history
YEARDSCRYoY
-33.82+4,736.09%
-0.70-91.73%
-8.45-61.29%
-21.84+207.21%
-7.11—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SyntekaBio Stock analysis

What does SyntekaBio do? SyntekaBio Inc. provides bioinformatics solutions through AI-driven software and services. The company develops and sells PMAP, a personal algorithm dielectric map platform using artificial intelligence, and offers clinical trial modeling and genome analysis services via big data. These services diagnose genetic diseases, select biomarker treatments, and predict disease risk. SyntekaBio also develops AI drug development technology and provides research services for candidate substances of immuno-cancer drugs. The primary customers for SyntekaBio's products include healthcare providers, research institutions, and pharmaceutical companies. Healthcare providers use the diagnostic and predictive services for patient care, while research institutions and pharmaceutical firms utilize the genome analysis and drug development technologies. The company's AI-driven tools are tailored to meet the needs of these segments, focusing on precision medicine and oncology applications. SyntekaBio's revenue streams come from software sales, service contracts for clinical trial modeling and genome analysis, and research services for immuno-cancer drug candidates. The company's AI drug development technology is a key offering, targeting pharmaceutical companies seeking to accelerate drug discovery and development processes. The firm's focus on AI and big data analytics positions it as a provider of specialized solutions in the bioinformatics sector. SyntekaBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SyntekaBio stock

Debt Service Coverage Ratio (DSCR) of SyntekaBio is -33.82 in 2022.

Debt Service Coverage Ratio (DSCR) of SyntekaBio changed from -0.70 to -33.82, representing a 4,736.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Service Coverage Ratio (DSCR) SyntekaBio since 2006 – with annual values, charts, and detailed analysis.

The DSCR measures a company's ability to service its debt obligations from operating income. A ratio above 1.0 indicates sufficient income to cover debt payments.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt Service Coverage Ratio (DSCR)'s SyntekaBio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — SyntekaBio

All Key Metrics — SyntekaBio